Article ; Online: Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies - A Danish population-based cohort study.
2021 Volume 118, Page(s) 102613
Abstract: ... We conducted a Danish population-based cohort study including all residents living within Capital Region ... and its relationship with immunosuppressants among patients with immune-mediated inflammatory diseases ... Background: Limited data exist regarding the disease course of coronavirus disease 2019 (COVID-19 ...
Abstract | Background: Limited data exist regarding the disease course of coronavirus disease 2019 (COVID-19) and its relationship with immunosuppressants among patients with immune-mediated inflammatory diseases (IMIDs). Therefore, this study aims to investigate the association between COVID-19, frequent rheumatological, dermatological, gastrointestinal, and neurological IMIDs and immunosuppressants. Methods: We conducted a Danish population-based cohort study including all residents living within Capital Region of Denmark and Region Zealand from January 28th, 2020 until September 15th, 2020 with the only eligibility criterion being a test for SARS-CoV-2 via reverse transcription-polymerase chain-reaction. Main outcomes included development of COVID-19, COVID-19-related hospitalization and mortality. Results: COVID-19 was less common among patients with IMIDs than the background population (n = 328/20,513 (1.60%) and n = 10,792/583,788(1.85%), p < 0.01, respectively). However, those with IMIDs had a significantly higher risk of COVID-19-related hospitalization (31.1% and 18.6%, p < 0.01, respectively) and mortality (9.8% and 4.3%, p < 0.01, respectively), which were associated with patients older than 65 years, and presence of comorbidities. Furthermore, systemic steroids were independently associated with a severe course of COVID-19 (Odds ratio (OR) = 3.56 (95%CI 1.83-7.10), p < 0.01), while biologic therapies were associated with a reduced risk hereof (OR = 0.47 (95%CI 0.22-0.95), p = 0.04). Patients suspending immunosuppressants due to COVID-19 had an increased risk of subsequent hospitalization (OR = 3.59 (95%CI 1.31-10.78), p = 0.02). Conclusion: This study found a lower occurrence, but a more severe disease course, of COVID-19 among patients with IMIDs, which was associated with the use of systemic steroids for IMIDs and suspension of other immunosuppressants. This study emphasizes the importance of weighing risks before suspending immunosuppressants during COVID-19. |
|||||
---|---|---|---|---|---|---|
MeSH term(s) | Adult ; Age Factors ; Aged ; COVID-19/diagnosis ; COVID-19/drug therapy ; COVID-19/epidemiology ; COVID-19 Nucleic Acid Testing ; Denmark/epidemiology ; Female ; Humans ; Immunosuppression ; Immunosuppressive Agents/administration & dosage ; Inflammation/diagnosis ; Inflammation/epidemiology ; Inflammation/therapy ; Male ; Middle Aged ; Risk Factors ; SARS-CoV-2 | |||||
Chemical Substances | Immunosuppressive Agents | |||||
Language | English | |||||
Publishing date | 2021-02-12 | |||||
Publishing country | England | |||||
Document type | Clinical Trial ; Journal Article ; Multicenter Study | |||||
ZDB-ID | 639452-8 | |||||
ISSN | 1095-9157 ; 0896-8411 | |||||
ISSN (online) | 1095-9157 | |||||
ISSN | 0896-8411 | |||||
DOI | 10.1016/j.jaut.2021.102613 | |||||
Shelf mark |
|
|||||
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 2368: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.